p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells

Genes and Development

Volumn 10, Issue 19, 1996, Pages 2438-2451

  Chen, Xinbin ^a,b   Ko, Linda J ^a   Jayaraman, Lata ^a   Prives, Carol ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

apoptosis; cell cycle arrest; DNA damage; p21 WAF1; p53

Indexed keywords

APOPTOSIS; ARTICLE; CELL CYCLE; DNA STRAND BREAKAGE; GENE FREQUENCY; GENE MUTATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

EID: 0029802591     PISSN: 08909369     EISSN: None     Source Type: Journal    
DOI: 10.1101/gad.10.19.2438     Document Type: Article

References (63)

1. Agarwal, M. L., A. Agarwal, W.R. Taylor, and G.R. Stark. 1995. p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc. Natl. Acad. Sci. 92: 8493-8497.
2. Attardi, L.D., S.W. Lowe, J. Brugarolas, and T. Jacks. 1996. Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene mediated apoptosis. EMBO J. 15: 3693-3701.
3. Baserga, R. 1994. Oncogenes and strategy of growth factors. Cell 79: 927-930.
4. Brugarolas, J., C. Chandrasekaran, J.I. Gordon, D. Beach, T. Jacks, and G.J. Hannon. 1995. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377: 552-557.
5. Boudreau, N., C.J. Sympton, Z. Werb, and M.J. Bissell. 1995. Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix. Science 267: 891-893.
6. Boudreau, N., Z. Werb, and M.J. Bissell. 1996. Suppression of apoptosis by base membrane requires three-dimensional tissue organization and withdrawal from the cell cycle. Proc. Acad. Sci. 93: 3509-3513.
7. Buckbinder, L., R. Talbott, S. Velasco-Miguel, I. Takenaka, B. Faha, B.R. Seizinger, and N. Kley. 1995. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377: 646-649.
8. Caelles, C., A. Helmberg, and M. Karin. 1994. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 370: 220-223.
9. Chen, C. and H. Okayama. 1987. High-efficiency transformation of mammalian cells by plasmid DNA. Mol. Cell. Biol. 7: 2745-2752.
10. Chen, P.-L., Y. Chen, R. Bookstein, and W.-H. Lee. 1990. Genetic mechanisms of tumor suppression by the human p53 gene. Science 250: 1576-1580.
11. Chen, X., G. Farmer, H. Zhu, R. Prywes, and C. Prives. 1993. Cooperative DNA binding of p53 with TFIID (TBP): A possible mechanism for transcriptional activation. Genes & Dev. 7: 1837-1849.
12. Chen, X., J. Bargonetti, and C. Prives. 1995. p53, through p21 (WAF1/CIP1), induces cyclin D1 synthesis. Cancer Res. 55: 4257-4263.
13. WAF1. Cancer Res. 55: 4536-4539.
14. CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82: 675-684.
15. El-Deiry, W.S., T. Tokino, V.E. Velculescu, D.B. Levy, R. Parsons, J.M. Trent, D. Lin, W.E. Mercer, K.W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825.
16. WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res. 55: 2910-2919.
17. Fisher, D.E. 1994. Apoptosis in cancer therapy: Crossing the threshold. Cell 78: 539-542.
18. Friedlander, P., Y. Haupt, C. Prives, and M. Oren. 1996. A mutant p53 that discriminates between p53 responsive genes cannot induce apoptosis. Mol. Cell. Biol. 16: 4961-4971.
19. Gossen, M. and H. Bujard. 1992. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. 89: 5547-5551.
20. Gottlieb, M.T. and M. Oren. 1996. p53 in growth control and neoplasia. Biochem. Biophys. Acta 1287: 77-102.
21. Gottlieb, E., S. Linder, and M. Oren. 1996. Relationship of sequence-specific transactivation and p53-regulated apoptosis in interleukin-3 dependent hematopoietic cells. Cell Growth & Diff. 7: 301-310.
22. Graeber, T.G., C. Osmanian, T. Jacks, D.E. Housman, C.J. Koch, S.W. Lowe, and A.J. Giaccia. 1996. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379: 88-91.
23. Halazonetis, T.D. and A.N. Kandil. 1993. Confirmational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants. EMBO J. 12: 5057-5064.
24. Harper, J.W., G.R. Adami, N. Wei, K. Keyomarsi, and S.J. Elledge. 1993. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816.
25. Haupt, Y., S. Rowan, E. Shaulian, K. Vousden, and M. Oren. 1995. Induction of apoptosis in HeLa cells by transactivation-deficient p53. Genes & Dev. 9: 2170-2183.
26. Hollstein, M., D. Sidransky, B. Vogelstein, and C.C. Harris. 1991. p53 mutations in human cancers. Science 253: 49-53.
27. Horikoshi, N., A. Usheva, J. Chen, A.J. Levine, R. Weinmann, and T. Shenk. 1995. Two domains of p53 interact with the TATA-binding protein, and the adenovirus 13S E1A protein disrupts the association, relieving p53-mediated transcriptional repression. Mol. Cell. Biol. 15: 227-234.
28. Hupp, T.R., D.W. Meek, C.A. Midgley, and D.P. Lane. 1992. Regulation of the specific DNA binding function of p53. Cell 71: 875-886.
29. Iwabuchi, K., P.L. Bartel, B. Li, R. Marraccino, and S. Fields. 1994. Two cellular proteins that bind to wild-type but not mutant p53. Proc. Natl. Acad. Sci. 91: 6098-6102.
30. Kastan, M.B., Q. Zhan, W.S. El-Deiry, F. Carrier, T. Jacks, W.V. Walsh, B.S. Plunkett, B. Vogelstein, and A.J. Fornace Jr. 1992. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71: 587-597.
31. Ko, L.J. and C. Prives. 1996. p53: Puzzle and paradigm. Genes & Dev. 10: 1054-1072.
32. Leveillard, T., L. Andera, N. Bissonnette, L. Schaeffer, L. Bracco, J.-M. Egly, and B. Wasylyk. 1996. Functional interactions between p53 and the TFIIH complex are affected by tumour-associated mutations. EMBO J. 15: 1615-1624.
33. Levine, A. 1993. The tumor suppressor genes. Annu. Rev. Biochem. 62: 623-651.
34. Lin, J., J. Chen, B. Elenbaas, and A.J. Levine. 1994. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes & Dev. 8: 1235-1246.
35. Lin, J.L., A.K. Teresky, and A.J. Levine. 1995. Two critical hydrophobic amino acids in the amino-terminal domain of the p53 protein are required for the gain of function phenotypes of human p53 mutants. Oncogene 10: 2387-2390.
36. Liu, X., C.W. Miller, P.H. Koeffler, and A.J. Berk. 1993. p53 activation domain binds the TATA-box binding polypeptide and a neighboring p53 domain inhibits transcription. Mol. Cell. Biol. 13: 3291-3300.
37. Lowe, S.W., H.E Ruley, T. Jacks, and D.E. Housman. 1993. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967.
38. Lu, H. and A.J. Levine. 1995. Human TAF31 protein is a transcriptional coactivator of the p53 protein. Proc. Natl. Acad. Sci. 92: 5154-5158.
39. Lu, X. and D.P. Lane. 1993. Differential induction of transcriptionally active p53 following UV or ionizing radiation: Defects in chromosome instability syndromes? Cell 75: 765-778.
40. Ludwig, R.L., S. Bates, and K.H. Vousden. 1996. Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol Cell. Biol. 16: 4952-4960.
41. Maltzman, W. and L. Czyzyk. 1984. UV irridiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol. Cell. Biol. 4: 1689-1694.
42. Martin, D.W., R.M. Munoz, M.A. Subler, and S. Deb. 1993. p53 binds to the TATA-binding protein-TATA complex. J. Biol. Chem. 268: 13062-13067.
43. Miyashita, T. and T.C. Reed. 1995. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293-299.
44. Nelson, W.G. and M.B. Kastan. 1994. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell. Biol. 14: 1815-1823.
45. Oltvai, Z.N., C.L. Milman, and S.J. Korsmeyer. 1993. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74: 609-619.
46. Pietenpol, J.A., T. Tokino, S. Thiagalingam, W.S. El-Deiry, K.W. Kinzler, and B.S. Vogelstein. 1994. Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc. Natl. Acad. Sci. 91: 1998-2002.
47. Prives, C. 1994. How loops, β sheets, and a helices help us to understand p53. Cell 78: 543-546.
48. Resnitzky, D., M. Gossen, H. Bujard, and S.I. Reed. 1994. Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system. Mol Cell Biol. 14: 1669-1679.
49. Renzing, J. and D.P. Lane. 1995. p53-dependent growth arrest following calcium phosphate-mediated transfection of murine fibroblasts. Oncogene 10: 1865-1868.
50. Sabbatini, P., J. Lin, A.J. Levine, and E. White. 1995. Essential role for p53-mediated transcription in E1A-induced apoptosis. Genes & Dev. 9: 2184-2192.
51. Seto, E., A. Usheva, G.P. Zambetti, J. Momand, N. Horikoshi, R. Weinmann, A.J. Levine, and T. Shenk. 1992. Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc. Natl. Acad. Sci. 89: 12028-12032.
52. Slobos, R.J.C., M.H. Lee, B.S. Plunkett, T.D. Kessi, B.O. Williams, T. Jacks, L. Hedrick, M.B. Kastan, and K.R. Cho. 1994. p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein. Proc. Natl. Acad. Sci. 91: 5320-5324.
53. Sturzbecher, H.-W., R. Brain, C. Addison, K. Rudge, M. Remm, M. Grimaldi, E. Keenan, and J.R. Jenkins. 1992. A C-terminal α-helix plus basic region motif is the primary structural determinant of p53 tetramerizarion. Oncogene 7: 1513-1523.
54. Thut, C., J.L. Chen, R. Klemm, and R. Tjian. 1995. p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60. Science 267: 100-104.
55. Van Meir, E.G., P.J. Polverini, V.R. Chazin, H.-J.S. Huang, N.D. Triolet, and W.K. Carvenee. 1994. Release of an inhibitor of angiogenesis upon induction of wild-type p53 expression in glioblastoma cells. Nature Genet. 8: 171-176.
56. Vogelstein, B. and K.W. Kinzler. 1992. p53 function and dysfunction. Cell 70: 523-526.
57. waf1/cip1. Genes & Dev. 8: 2817-2830.
58. Wang, X.W., H. Yeh, L. Schaeffer, R. Roy, V. Moncollin, J.-M. Egly, Z. Wang, E.G. Friedberg, M.K. Evans, B.C. Taffe, V.A. Bohr, G. Weeda, J.H.J. Hoeijmakers, K. Forrester, and C.C. Harris. 1995. p53 modulation of TFIIH-associated nucleotide excision repair activity. Nature Genet. 10: 188-193.
59. Wang, X., W. Vermeulen, J.D. Coursen, M. Gibson, S.E. Lupold, K. Forrester, G. Xu, L. Elmore, H. Yeh, J.H.J. Hoeijmakers, and G.G. Harris. 1996. The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway. Genes & Dev. 10: 1219-1232.
60. White, E. 1996. Life, death, and the pursuit of apoptosis. Genes & Dev. 10: 1-15.
61. Williams, G.T. and C.A. Smith. 1993. Molecular regulation of apoptosis: Genetic controls on cell death. Cell 74: 777-779.
62. Xiao, H., A. Pearson, B. Coulombe, R. Truant, S. Zhang, J.L. Regier, S.J. Triezenberg, D. Reinberg, O. Flores, C.J. Ingles, and J. Greenblatt. 1994. Binding of basal transcription factor TFIIH to the acidic activation domains of VP16 and p53. Mol. Cell. Biol. 14: 7013-7024.
63. Xiong, Y., G.J. Hannon, H. Zhang, D. Casso, R. Kobayashi, and D. Beach. 1993. p21 is a universal inhibitor of cyclin kinases. Nature 366: 701-704.